By Helgi Library - April 2, 2020
Pfizer Czech Republic's total assets reached CZK 2,549 mil at the end of 2017, up 24.3% compared to the previous year. ...
By Helgi Library - April 2, 2020
Pfizer Czech Republic's total assets reached CZK 2,549 mil at the end of 2017, up 24.3% compared to the previous year. ...
| Profit Statement | 2015 | 2016 | 2017 | |
| Sales | CZK mil | 3,122 | 3,243 | 3,586 |
| Gross Profit | CZK mil | 311 | 366 | 445 |
| EBITDA | CZK mil | 110 | 120 | 156 |
| EBIT | CZK mil | 98.2 | 98.0 | 132 |
| Financing Cost | CZK mil | 6.38 | 4.31 | 6.17 |
| Pre-Tax Profit | CZK mil | 91.9 | 93.7 | 126 |
| Net Profit | CZK mil | 75.4 | 73.4 | 103 |
| Balance Sheet | 2015 | 2016 | 2017 | |
| Total Assets | CZK mil | 1,937 | 2,051 | 2,549 |
| Non-Current Assets | CZK mil | 197 | 195 | 312 |
| Current Assets | CZK mil | 1,737 | 1,853 | 2,234 |
| Working Capital | CZK mil | 1,107 | 1,234 | 1,617 |
| Shareholders' Equity | CZK mil | 1,180 | 1,253 | 1,355 |
| Liabilities | CZK mil | 757 | 798 | 1,194 |
| Total Debt | CZK mil | 0 | 0 | 338 |
| Net Debt | CZK mil | -4.12 | -5.68 | 329 |
| Ratios | 2015 | 2016 | 2017 | |
| ROE | % | 5.24 | 6.03 | 7.86 |
| ROCE | % | 7.83 | 5.37 | 6.11 |
| Gross Margin | % | 9.96 | 11.3 | 12.4 |
| EBITDA Margin | % | 3.54 | 3.69 | 4.36 |
| EBIT Margin | % | 3.15 | 3.02 | 3.68 |
| Net Margin | % | 2.41 | 2.26 | 2.86 |
| Net Debt/EBITDA | -0.037 | -0.047 | 2.10 | |
| Net Debt/Equity | % | -0.350 | -0.453 | 24.2 |
| Cost of Financing | % | ... | ... | 3.65 |
| Cash Flow | 2015 | 2016 | 2017 | |
| Total Cash From Operations | CZK mil | ... | 26.2 | -700 |
| Total Cash From Investing | CZK mil | ... | -24.6 | 703 |
| Total Cash From Financing | CZK mil | ... | 0 | 0 |
| Net Change In Cash | CZK mil | ... | 1.55 | 3.21 |
| Cash Conversion Cycle | days | 131 | 141 | 166 |
| Cash Earnings | CZK mil | 87.5 | 95.0 | 127 |
| Free Cash Flow | CZK mil | ... | 1.55 | 3.21 |
Get all company financials in excel:
| summary | Unit | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
| income statement | |||||||||||||||||
| Sales | CZK mil | 6,807 | 3,118 | 5,407 | 4,947 | 3,122 | |||||||||||
| Gross Profit | CZK mil | 755 | 287 | 502 | 475 | 311 | |||||||||||
| EBIT | CZK mil | 303 | 63.4 | 170 | 170 | 98.2 | |||||||||||
| Net Profit | CZK mil | 231 | 48.1 | 144 | 134 | 75.4 | |||||||||||
| ROE | % | 25.2 | 4.63 | 11.1 | 8.21 | 5.24 | |||||||||||
| EBIT Margin | % | 4.45 | 2.03 | 3.15 | 3.44 | 3.15 | |||||||||||
| Net Margin | % | 3.40 | 1.54 | 2.67 | 2.70 | 2.41 | |||||||||||
| Employees | 253 | 203 | 183 | 170 | 121 | ||||||||||||
| balance sheet | |||||||||||||||||
| Total Assets | CZK mil | 2,885 | 2,530 | 2,812 | 2,922 | 1,937 | |||||||||||
| Non-Current Assets | CZK mil | 16.5 | 9.46 | 7.30 | 99.1 | 197 | |||||||||||
| Current Assets | CZK mil | 2,866 | 2,518 | 2,798 | 2,818 | 1,737 | |||||||||||
| Shareholders' Equity | CZK mil | 1,034 | 1,043 | 1,562 | 1,696 | 1,180 | |||||||||||
| Liabilities | CZK mil | 1,851 | 1,487 | 1,249 | 1,226 | 757 | |||||||||||
| Non-Current Liabilities | CZK mil | 0.438 | 0.438 | 0 | 0 | 0 | |||||||||||
| Current Liabilities | CZK mil | 1,835 | 1,474 | 1,226 | 1,212 | 742 | |||||||||||
| Net Debt/EBITDA | 2.16 | -1.32 | -0.141 | -1.65 | -0.037 | ||||||||||||
| Net Debt/Equity | % | 66.1 | -8.43 | -1.56 | -16.8 | -0.350 | |||||||||||
| Cost of Financing | % | ... | ... | ... | 4.09 | 0.877 | ... | ... | ... | ... | |||||||
| cash flow | |||||||||||||||||
| Total Cash From Operations | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | ||||||||
| Total Cash From Investing | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | ||||||||
| Total Cash From Financing | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | ||||||||
| Net Change In Cash | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... |
| income statement | Unit | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
| income statement | |||||||||||||||||
| Sales | CZK mil | 6,807 | 3,118 | 5,407 | 4,947 | 3,122 | |||||||||||
| Cost of Goods & Services | CZK mil | 6,051 | 2,831 | 4,905 | 4,472 | 2,811 | |||||||||||
| Gross Profit | CZK mil | 755 | 287 | 502 | 475 | 311 | |||||||||||
| Staff Cost | CZK mil | 389 | 127 | 266 | 271 | 175 | |||||||||||
| Other Cost | CZK mil | 50.5 | 93.9 | 63.8 | 31.9 | 25.7 | |||||||||||
| EBITDA | CZK mil | 316 | 66.4 | 173 | 172 | 110 | |||||||||||
| Depreciation | CZK mil | 13.5 | 2.99 | 2.56 | 2.12 | 12.2 | |||||||||||
| EBIT | CZK mil | 303 | 63.4 | 170 | 170 | 98.2 | |||||||||||
| Financing Cost | CZK mil | 17.5 | 3.75 | 0.699 | 4.58 | 6.38 | |||||||||||
| Extraordinary Cost | CZK mil | -0.007 | 0.002 | -8.21 | 0.063 | 0 | |||||||||||
| Pre-Tax Profit | CZK mil | 285 | 59.6 | 178 | 165 | 91.9 | |||||||||||
| Tax | CZK mil | 53.8 | 11.6 | 33.5 | 31.6 | 16.5 | |||||||||||
| Minorities | CZK mil | 0 | 0 | 0 | 0 | 0 | |||||||||||
| Net Profit | CZK mil | 231 | 48.1 | 144 | 134 | 75.4 | |||||||||||
| growth rates | |||||||||||||||||
| Total Revenue Growth | % | ... | 4.32 | -54.2 | 73.4 | -8.51 | -36.9 | ||||||||||
| Operating Cost Growth | % | ... | -17.5 | -49.8 | 49.5 | -8.06 | -33.8 | ||||||||||
| EBITDA Growth | % | ... | 93.1 | -79.0 | 160 | -0.368 | -35.9 | ||||||||||
| EBIT Growth | % | ... | 114 | -79.1 | 169 | -0.115 | -42.2 | ||||||||||
| Pre-Tax Profit Growth | % | ... | 132 | -79.1 | 198 | -6.94 | -44.5 | ||||||||||
| Net Profit Growth | % | ... | 137 | -79.2 | 200 | -7.25 | -43.7 | ||||||||||
| ratios | |||||||||||||||||
| ROE | % | 25.2 | 4.63 | 11.1 | 8.21 | 5.24 | |||||||||||
| ROCE | % | ... | 13.9 | 4.56 | 18.1 | 16.1 | 7.83 | ||||||||||
| Gross Margin | % | 11.1 | 9.20 | 9.29 | 9.61 | 9.96 | |||||||||||
| EBITDA Margin | % | 4.64 | 2.13 | 3.20 | 3.48 | 3.54 | |||||||||||
| EBIT Margin | % | 4.45 | 2.03 | 3.15 | 3.44 | 3.15 | |||||||||||
| Net Margin | % | 3.40 | 1.54 | 2.67 | 2.70 | 2.41 | |||||||||||
| Cost of Financing | % | ... | ... | ... | 4.09 | 0.877 | ... | ... | ... | ... | |||||||
| Net Debt/EBITDA | 2.16 | -1.32 | -0.141 | -1.65 | -0.037 |
| balance sheet | Unit | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
| balance sheet | |||||||||||||||||
| Non-Current Assets | CZK mil | 16.5 | 9.46 | 7.30 | 99.1 | 197 | |||||||||||
| Property, Plant & Equipment | CZK mil | 16.3 | 9.44 | 7.30 | 5.16 | 3.21 | |||||||||||
| Intangible Assets | CZK mil | 0.181 | 0.026 | 0 | 93.9 | 194 | |||||||||||
| Current Assets | CZK mil | 2,866 | 2,518 | 2,798 | 2,818 | 1,737 | |||||||||||
| Inventories | CZK mil | 959 | 933 | 1,095 | 813 | 716 | |||||||||||
| Receivables | CZK mil | 1,305 | 900 | 973 | 733 | 1,007 | |||||||||||
| Cash & Cash Equivalents | CZK mil | 172 | 87.9 | 24.3 | 284 | 4.12 | |||||||||||
| Total Assets | CZK mil | 2,885 | 2,530 | 2,812 | 2,922 | 1,937 | |||||||||||
| Shareholders' Equity | CZK mil | 1,034 | 1,043 | 1,562 | 1,696 | 1,180 | |||||||||||
| Of Which Minority Interest | CZK mil | 0 | 0 | 0 | 0 | 0 | |||||||||||
| Liabilities | CZK mil | 1,851 | 1,487 | 1,249 | 1,226 | 757 | |||||||||||
| Non-Current Liabilities | CZK mil | 0.438 | 0.438 | 0 | 0 | 0 | |||||||||||
| Long-Term Debt | CZK mil | 0 | 0 | 0 | 0 | 0 | |||||||||||
| Deferred Tax Liabilities | CZK mil | 0 | 0 | 0 | 0 | 0 | |||||||||||
| Current Liabilities | CZK mil | 1,835 | 1,474 | 1,226 | 1,212 | 742 | |||||||||||
| Short-Term Debt | CZK mil | 856 | 0 | 0 | 0 | 0 | |||||||||||
| Trade Payables | CZK mil | 734 | 1,280 | 1,039 | 1,023 | 616 | |||||||||||
| Provisions | CZK mil | 16.2 | 12.9 | 23.3 | 13.5 | 15.0 | |||||||||||
| Equity And Liabilities | CZK mil | 2,885 | 2,530 | 2,812 | 2,922 | 1,937 | |||||||||||
| growth rates | |||||||||||||||||
| Total Asset Growth | % | ... | -3.91 | -12.3 | 11.1 | 3.91 | -33.7 | ||||||||||
| Shareholders' Equity Growth | % | ... | 28.8 | 0.865 | 49.8 | 8.56 | -30.5 | ||||||||||
| Net Debt Growth | % | ... | -703 | -113 | -72.3 | 1,069 | -98.5 | ||||||||||
| Total Debt Growth | % | ... | ... | ... | ... | ... | ... | -100 | ... | ... | ... | ... | ... | ||||
| ratios | |||||||||||||||||
| Total Debt | CZK mil | 856 | 0 | 0 | 0 | 0 | |||||||||||
| Net Debt | CZK mil | 684 | -87.9 | -24.3 | -284 | -4.12 | |||||||||||
| Working Capital | CZK mil | 1,530 | 552 | 1,028 | 523 | 1,107 | |||||||||||
| Capital Employed | CZK mil | 1,546 | 561 | 1,035 | 622 | 1,304 | |||||||||||
| Net Debt/Equity | % | 66.1 | -8.43 | -1.56 | -16.8 | -0.350 | |||||||||||
| Cost of Financing | % | ... | ... | ... | 4.09 | 0.877 | ... | ... | ... | ... |
| cash flow | Unit | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
| cash flow | |||||||||||||||||
| Net Profit | CZK mil | 231 | 48.1 | 144 | 134 | 75.4 | |||||||||||
| Depreciation | CZK mil | 13.5 | 2.99 | 2.56 | 2.12 | 12.2 | |||||||||||
| Non-Cash Items | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | ... | |||||||
| Change in Working Capital | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | ... | |||||||
| Total Cash From Operations | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | ||||||||
| Capital Expenditures | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | ||||||||
| Other Investments | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | ||||||||
| Total Cash From Investing | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | ||||||||
| Issuance Of Shares | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ||
| Issuance Of Debt | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | ... | |||||||
| Total Cash From Financing | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | ||||||||
| Net Change In Cash | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | ||||||||
| ratios | |||||||||||||||||
| Days Sales Outstanding | days | 70.0 | 105 | 65.7 | 54.1 | 118 | |||||||||||
| Days Sales Of Inventory | days | 57.8 | 120 | 81.5 | 66.3 | 92.9 | |||||||||||
| Days Payable Outstanding | days | 44.3 | 165 | 77.4 | 83.5 | 80.0 | |||||||||||
| Cash Conversion Cycle | days | 83.6 | 60.5 | 69.8 | 36.9 | 131 | |||||||||||
| Cash Earnings | CZK mil | 245 | 51.0 | 147 | 136 | 87.5 | |||||||||||
| Free Cash Flow | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... |
| other data | Unit | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
| other data | |||||||||||||||||
| ROA | % | 7.86 | 1.77 | 5.40 | 4.67 | 3.10 | |||||||||||
| Gross Margin | % | 11.1 | 9.20 | 9.29 | 9.61 | 9.96 | |||||||||||
| Employees | 253 | 203 | 183 | 170 | 121 | ||||||||||||
| Cost Per Employee | USD per month | 7,241 | 2,655 | 6,187 | 6,218 | 5,044 | |||||||||||
| Cost Per Employee (Local Currency) | CZK per month | 128,064 | 51,930 | 121,053 | 132,894 | 120,395 | |||||||||||
| Staff Cost (As % Of Total Cost) | % | 5.98 | 4.14 | 5.08 | 5.68 | 5.78 | |||||||||||
| Effective Tax Rate | % | 18.9 | 19.4 | 18.9 | 19.1 | 18.0 | |||||||||||
| Domestic Sales | CZK mil | 3,372 | 1,524 | 2,727 | 2,528 | 1,254 | |||||||||||
| Capital Expenditures (As % of Sales) | % | ... | ... | ... | ... | ... | ... | ... | ... | ||||||||
| Revenues From Abroad | CZK mil | 3,436 | 1,594 | 2,680 | 2,418 | 1,868 | |||||||||||
| Revenues From Abroad (As % Of Total) | % | 50.5 | 51.1 | 49.6 | 48.9 | 59.8 | |||||||||||
| Sales of Goods | CZK mil | 3,395 | 1,502 | 2,710 | 2,524 | 2,824 | |||||||||||
| Sales Of Services | CZK mil | 3,413 | 1,616 | 2,697 | 2,422 | 298 |
Get all company financials in excel:
Pfizer Czech Republic is a Czech Republic-based subsidiary of the multinational pharmaceutical corporation Pfizer. Pfizer, Inc. develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, diabetology/endocrinology, and neurology. Pfizer's products include the blockbuster drug Lipitor (atorvastatin), used to lower LDL blood cholesterol; Lyrica (pregabalin for neuropathic pain/fibromyalgia); Diflucan (fluconazole), an oral antifungal medication; Zithromax (azithromycin), an antibiotic; Viagra (sildenafil, for erectile dysfunction); and Celebrex/Celebra (celecoxib), an anti-inflammatory drug. Pfizer was founded by cousins Charles Pfizer and Charles Erhart in New York City in 1849 as a manufacturer of fine chemicals
Pfizer Czech Republic has been growing its sales by a year on average in the last 5 years. EBITDA has grown on average by 18.7% a year during that time to total of CZK 156 mil in 2017, or 4.36% of sales. That’s compared to 3.65% average margin seen in last five years.
The company netted CZK 103 mil in 2017 implying ROE of 7.86% and ROCE of 6.11%. Again, the average figures were 7.68% and 10.7%, respectively when looking at the previous 5 years.
Pfizer Czech Republic’s net debt amounted to CZK 329 mil at the end of 2017, or 24.2% of equity. When compared to EBITDA, net debt was 2.10x, up when compared to average of 0.045x seen in the last 5 years.
Helgi Library 
